CoChat

Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

= 10). Patients in the favorable cohort had high intratumoral CD8 T cell density and IFN-γ response gene signature and/or antigen-specific T cell responses. Two patients with a relatively low TMB had T cell responses against unique neoantigens. Moreover, six of nine patients in the favorable group are still alive at the time of analysis, with survival ranging from 33 to 54 months after treatment. All 10 patients in the unfavorable cohort have succumbed to their disease and had survival ranging from 0.6 to 10.3 months. Collectively, our data indicate that immunological correlates associated with effector T cell responses are observed in patients with metastatic prostate cancer who benefit from ICB.

Overview

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aaz3577

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 159

Metadata

Authors
Subudhi, S. K., Vence, L., Zhao, H., Blando, J., Yadav, S. S., Xiong, Q., Reuben, A., Aparicio, A., Corn, P. G., Chapin, B. F., Pisters, L. L., Troncoso, P., Tidwell, R. S., Thall, P., Wu, C.-J., Zhang, J., Logothetis, C. L., Futreal, A., Allison, J. P., & Sharma, P.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Corresponding author
  • Allison, James P.
  • Sharma, Padmanee
Venue
Science Translational Medicine
Published
2020-04
Volume
12
Issue
537
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W3014592760
Cited by
158
References
36
Citations by year
2026: 10 · 2025: 23 · 2024: 17 · 2023: 21 · 2022: 34 · 2021: 36 · 2020: 16
FWCI
9.71
Type
journal article
Language
en
Open access
closed
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Prostate Cancer Foundation
  • University of Texas MD Anderson Cancer Center
  • Stand Up To Cancer
  • Parker Institute for Cancer Immunotherapy
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
ipilimumab, prostate cancer, neoantigens, immune checkpoint blockade, tumor mutational burden, CD8+ T cells, IFN-gamma response, antigen-specific T cell responses, metastatic prostate cancer, survival, immune correlates
MeSH terms
Antineoplastic Agents, Immunological, Ipilimumab, Humans, Male, Prostatic Neoplasms, Biomarkers, Tumor, Cohort Studies, CD8-Positive T-Lymphocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.